前药
体内
结合
白蛋白
药理学
化学
葡萄糖醛酸
生物结合
药物输送
血清白蛋白
医学
生物化学
新陈代谢
生物
生物技术
有机化学
数学分析
数学
作者
Rémi Châtre,Justin Lange,Elodie Péraudeau,Pauline Poinot,Stéphanie Lerondel,Alain Le Pape,Jonathan A. Clarhaut,Brigitte Renoux,Sébastien Papot
标识
DOI:10.1016/j.jconrel.2020.08.008
摘要
The development of selective anticancer drugs avoiding side effects met in the course of almost all current treatments is of major interest for cancer patients. Here, we report on a novel β-glucuronidase-responsive drug delivery system allowing the in vivo synthesis of triple-loaded albumin conjugate. Following intravenous administration, the glucuronide prodrug reacts in the blood stream with the cysteine-34 residue of circulating albumin through thio-Michael addition, enabling the bioconjugation of three Monomethylauristatin E (MMAE) molecules to the plasmatic protein. The albumin conjugate then accumulates in malignant tissues where tumor-associated β-glucuronidase triggers the selective release of the whole transported drugs. By operating this way, the trimeric glucuronide prodrug produces remarkable anticancer activity on orthotopic MIA PaCa-2 pancreatic tumors, leading to dramatic reduction or even remission of tumors (3/8 mice).
科研通智能强力驱动
Strongly Powered by AbleSci AI